ArticleNature2023
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 3 pooled it
23.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 3 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Emerging Insights into the Role of the Microbiome in Brain Gliomas: A Systematic Review of Recent Evidence.International journal of molecular sciences · 2025Pooled it
- A scientometric analysis of global research on gut microbiota and glioma.Frontiers in oncology · 2025Pooled it
- Gut microbiota and gastrointestinal tumors: insights from a bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation.Annals of medicine · 2026Review
- Abundant CD8British journal of cancer · 2026Article
- Review
- The Microbiome in Glioblastoma: Mechanisms, Tumor-Immune Interactions, and Translational Perspectives.MicrobiologyOpen · 2026Review
- The emerging role of microbiota in neuro-oncology.Nature reviews. Neurology · 2026Review
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.Nature reviews. Cancer · 2026Review
- Microbiota-Neuroinflammation Crosstalk in Primary Brain Tumors: Focus on Glioblastoma.Brain and behavior · 2026Review
- Microbiota-Derived Corisin Is Elevated in Early Cervical Neoplasia and Drives Pathogenic Cellular Programs.Cells · 2026Article
- Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential.Genes & diseases · 2026Review
- Gut microbiota composition and tumor immune features in meningioma patients.Microbiology spectrum · 2026Article
- Gut microbiota and cancer immunotherapy: from dysbiosis to personalized immune checkpoint blockade optimization.Folia microbiologica · 2026Review
- Contextualizing TNature reviews. Immunology · 2026Review
- Breast tumor microbiome regulates anti-tumor immunity and T cell-associated metabolites.Scientific reports · 2026Article
- Harnessing the Microbiome in Cancer Immunotherapy: Regulation, Prediction, and Therapeutic Targeting.Annual review of immunology · 2026Review
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- Relationship Between Gut Microbiota and Cancer Neuro-Immunity.Microbial biotechnology · 2026Review
- Circulating sPD-L1 as a tumor microenvironment-derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer.Cancer immunology, immunotherapy : CII · 2026Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 7 institutions in 6 countries.
Reza NaghavianNeuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-1328-4095
Wolfgang FaigleNeuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, Zurich, Switzerland.
Pietro OldratiNeuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-5551-4306
Jian WangNeuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, Zurich, Switzerland.
Nora C ToussaintNEXUS Personalized Health Technologies, ETH Zurich, Schlieren, Switzerland.ORCID http://orcid.org/0000-0001-7911-7647
Yuhan QiuNeuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-5774-7661
Gioele MediciClinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-2279-6014
Marcel WackerDepartment of Peptide-based Immunotherapy, University of Tübingen, University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-8185-140X
Lena K FreudenmannInstitute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
Pierre-Emmanuel BontéImmunity and Cancer, Institut Curie, PSL University, INSERM U932, Paris, France.ORCID http://orcid.org/0000-0002-9732-5826
Michael WellerLaboratory of Molecular Neuro-Oncology, Department of Neurology and Clinical Neuroscience, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-1748-174X
Luca RegliClinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-4639-4474
Sebastian AmigorenaImmunity and Cancer, Institut Curie, PSL University, INSERM U932, Paris, France.ORCID http://orcid.org/0000-0001-8583-8416
Hans-Georg RammenseeInstitute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
Juliane S WalzDepartment of Peptide-based Immunotherapy, University of Tübingen, University Hospital Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0001-6404-7391
Silvio D BruggerDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-9492-9088
Malte MohmeDepartment of Neurosurgery, University Hospital Hamburg Eppendorf, University of Hamburg, Hamburg, Germany.ORCID http://orcid.org/0000-0003-0627-9092
Yingdong ZhaoComputational and Systems Biology Branch, Biometric Research Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA.
Mireia Sospedra *Neuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, Zurich, Switzerland.
Marian C Neidert *Clinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Roland MartinNeuroimmunology and MS Research Section (NIMS), Neurology Clinic, University of Zurich, University Hospital Zurich, Zurich, Switzerland. roland.martin@uzh.ch.ORCID http://orcid.org/0000-0002-0982-1329
University of Zurich · CHGerman Cancer Research Center · DEInserm · FRSIB Swiss Institute of Bioinformatics · CHUniversität Hamburg · DEUniversity of Science and Technology of China · CNZimmer Biomet (United States) · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial organisms have key roles in numerous physiological processes in the human body and have recently been shown to modify the response to immune checkpoint inhibitors
Indexed as
Antigens, NeoplasmBacteriaBacterial ProteinsGlioblastomaLymphocytes, Tumor-InfiltratingPeptide FragmentsCancer VaccinesCD4-Positive T-LymphocytesCell Line, TumorGastrointestinal MicrobiomeHistocompatibility Antigens Class IIHLA AntigensHumansSymbiosisAntigens, NeoplasmBacterial ProteinsCancer VaccinesHistocompatibility Antigens Class IIHLA AntigensPeptide Fragments
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.